Available online at www.sciencedirect.com
SCIENCE DIRECT®
Biochemical Pharmacology 65 (2003) 1915–1916
Erratum
Biochemical Pharmacology
www.elsevier.com/locate/biochempharm

# Erratum to "Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen α (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2" [Biochem. Pharmacol. 65 (2003) 813–821]☆

Julie Catusse*, Anne Liotard, Bruno Loillier, Didier Pruneau, Jean-Luc Paquet

*Groupe de Pharmacochimie des Récepteurs, Laboratoire Fournier SA, 50 route de Dijon, 21121 Daix, France*

The Publisher regrets that errors occurred in Table 1 and Fig. 3A of the above article and apologises for any confusion this may have caused. The correct versions are given below.

Table 1
Ligand binding selectivity of wild-type and mutant or chimeric receptors

| Constructs | CXC chemokine binding affinity ($EC_{50}$, nM) | | | | | |
|---|---|---|---|---|---|---|
| | [$^{125}$I]-CXCL8 | | | [$^{125}$I]-CXCL1 | | |
| | CXCL8 | CXCL1 | SB 225002 | CXCL8 | CXCL1 | SB 225002 |
| CXCR1 | 1.4 ± 0.7 | ND | | | | |
| CXCR2 | 1.2 ± 0.8 | 1.0 ± 0.5 | 9.9 ± 5.1 | 0.7 ± 0.1 | 0.9 ± 0.3 | 87.9 ± 23.0 |
| N1-2 | 0.4 ± 0.09 | ND | 331.0 | NS | NS | NS |
| N2-1 | NS | NS | NS | NS | NS | NS |
| EC2-1-2 | NS | NS | NS | 1.1 ± 0.7 | 1.1 ± 0.6 | 84.5 ± 24.2 |
| FXVXI-50-VXIXA | 0.7 ± 0.3 | 2.4 ± 0.5 | 48.6 ± 29.8 | 2.1 ± 1.3 | 1.0 ± 0.5 | 88.3 ± 10.7 |
| LL-174-MN | 1.7 ± 1.2 | 0.6 ± 0.3 | 10.8 ± 0.5 | 0.6 ± 0.3 | 1.9 ± 1.1 | 17.2 ± 2.1 |
| N-203-D | 0.1 ± 0.05 | 0.3 ± 0.1 | 240.0 ± 10.5 | 0.5 ± 0.1 | 0.6 ± 0.2 | 29.2 ± 8.0 |
| N-206-K | 0.2 ± 0.09 | 1.0 ± 0.5 | 65.8 ± 28.5 | 0.9 ± 0.1 | 0.5 ± 0.2 | 81.4 ± 10.1 |
| QS-216-HT | 0.1 ± 0.03 | 0.3 ± 0.05 | 30.6 ± 4.8 | 0.3 ± 0.2 | 0.8 ± 0.3 | 130.1 ± 53.2 |
| LI-225-FV | 0.3 ± 0.1 | 1.3 ± 0.2 | ND | 0.9 ± 0.2 | 0.4 ± 0.02 | 42.4 ± 9.8 |
| HXD-291-NXG | 1.6 ± 1.0 | ND | ND | 7.1 ± 0.1 | 0.4 ± 0.2 | 42.5 ± 15.8 |
| I-304-F | 16.3 ± 9.4 | 0.2 ± 0.01 | 10.9 ± 0.2 | 0.3 ± 0.1 | 0.3 ± 0.1 | 10.9 ± 2.1 |
| L-312-I | 5.4 ± 0.9 | 0.8 ± 0.8 | ND | NS | NS | NS |

The ligand binding selectivity of each receptor was determined on Jurkat cells exposed to 0.15 nM radiolabeled chemokine and varying concentration of cold chemokine or non-peptide antagonist as described in Section 2. Values shown correspond to the mean of three independent experiments in duplicate ± SEM. NS: no specific binding of the radiolabeled ligand; ND: no displacement of the radiolabeled chemokine by the cold ligand.

☆ doi of the original article: 10.1016/S0006-2952(02)01619-2.
* Corresponding author. Tel.: +33-3-80-44-77-54; fax: +33-3-80-44-76-00.
*E-mail address:* j.catusse@fournier.fr (J. Catusse).


doi:10.1016/S0006-2952(03)00295-8

| Construct | Agonist Potency $EC_{50}$ (nM) | | SB 225002 Antagonist Potency $IC_{50}$ (nM) | |
|---|---|---|---|---|
| | **CXCL8** | **CXCL1** | **CXCL8** | CXCL1 |
| **CXCR2** | 5.9 | 17.0 | 25 | 61 |
| **N1-2** | >100 | >100 | 130 | 25 |
| **N-203-D** | 13.5 | 28.5 | 300 | 490 |
| **N-206-K** | 3.8 | 15.7 | 650 | 390 |
| **LI-225-FV** | NR | NR | | |
| **I-304-F** | >100 | >100 | 19 | 21 |

Fig. 3. (A) Inhibition by SB 225002 of agonist-induced intracellular calcium release in BaF-3 cells. (A) Transfected BaF-3 cells were tested for their ability to release intracellular calcium in response to various concentrations of CXCL8 or CXCL1 (3–1000 nM) and to evaluate the ability of SB 225002 to inhibit it. The data are expressed as arbitrary fluorescence units normalized to the initial baseline level and maximum calcium release (cf. Section 2). $EC_{50}$ were determined by non-linear regression using GraphPad Prism software. The values are the means from three independent experiments in duplicate. NR: no response for agonist concentration $\leq 1$ μM, >100: response observed with too high dose stimulation for determination of an $EC_{50}$.